Sanofi Aventis gets EU green light for Jevtana
This article was originally published in Scrip
In line with the positive recommendation from the European Medicine Agency's CHMP, the European Commission has approved sanofi-aventis' Jevtana cabazitaxel, in combination with prednisone or prednisolone, to treat second-line metastatic hormone-refractory prostate cancer (mHRPC) patients previously treated with a docetaxel-containing regimen. The semi-synthetic taxane is approved in the US for the same indication.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.